RxDoctor Payments Data

Maurice Betesh

Podiatry · Brooklyn, NYNPI 1033564034

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Stryker accounts for 69.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $220, more than ten times the $20 reported in 2020. Among podiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$315in general payments, 2019–2025

Across 6 payments — averaging $52.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$220
  • Smith+Nephew$35
  • Orthofix Medical, Inc.$22
  • Abbott$20
  • Nevro Corp.$18

What the payments were for

  • Food & beverage$315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker2$220
Smith+Nephew1$35
Orthofix Medical, Inc.1$22
Abbott1$20
Nevro Corp.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$315 in reported general payments places this provider in the 90th percentile of 225 podiatry providers in New York.

See all podiatry providers in New York

Medicare billing

Part B allowed, 2024
$533,741
Medicare patients
989
Services billed
5,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxepin Hcl41$30,722
Budesonide ErBudesonide33$30,376
Diflorasone Diacetate23$16,914
Clobetasol Propionate28$12,264
Chlorpromazine Hcl15$11,870
Caspofungin Acetate31$8,648
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc26$6,455
Fluocinonide11$4,188
Diclofenac Sodium23$4,012
Betamethasone Dipropionate21$3,371
Ciclopirox53$1,548
Ammonium Lactate85$1,480
Clotrimazole27$758
Cephalexin17$51
Meloxicam19$30

Paid to pharmacies, not to this prescriber.

Other podiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →